These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39257196)

  • 1. Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes.
    Bantounou MA; Sardellis P; Plascevic J; Awaes-Mahmood R; Kaczmarek J; Black Boada D; Thuemmler R; Philip S
    ESC Heart Fail; 2024 Sep; ():. PubMed ID: 39257196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Bantounou MA; Sardellis P; Thuemmler R; Black Boada D; Kaczmarek J; Mahmood R; Plascevic J; Philip S
    Diabetes Obes Metab; 2024 Feb; 26(2):710-720. PubMed ID: 38031239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
    Bhatt AS; Bhatt DL; Steg PG; Szarek M; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Testani JM; Wilcox CS; Davies M; Pitt B; Kosiborod MN
    J Am Coll Cardiol; 2024 Sep; 84(12):1078-1088. PubMed ID: 39260929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
    Musso G; Gambino R; Cassader M; Paschetta E
    BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of the Potential Role of Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor-in the Treatment of Heart Failure.
    Tran BAC; White RT; Bullers K; Cornelio CK
    J Pharm Technol; 2024 Oct; 40(5):248-256. PubMed ID: 39391325
    [No Abstract]   [Full Text] [Related]  

  • 6. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.
    Long A; Salvo M
    Ann Pharmacother; 2024 Sep; 58(9):935-946. PubMed ID: 38014844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY; Liu SY; Yin DG
    Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P; Tunnicliffe DJ; Toyama T; Palmer SC; Saglimbene VM; Ruospo M; Gargano L; Stallone G; Gesualdo L; Strippoli GF
    Cochrane Database Syst Rev; 2024 May; 5(5):CD015588. PubMed ID: 38770818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis.
    Li J; Zhu C; Liang J; Hu J; Liu H; Wang Z; Guan R; Chow J; Yan S; Li L; Ma F; Ma G
    Front Pharmacol; 2023; 14():1303694. PubMed ID: 38044937
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
    Posch MG; Walther N; Ferrannini E; Powell DR; Banks P; Wason S; Dahmen R
    Diabetes Care; 2022 Sep; 45(9):2118-2126. PubMed ID: 35817022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
    Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
    Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
    Koufakis T; Mustafa OG; Tsimihodimos V; Ajjan RA; Kotsa K
    Drugs; 2021 Aug; 81(12):1365-1371. PubMed ID: 34232488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials.
    Zhou F; Du N; Zhou L; Wang C; Ren H; Sun Q
    Front Endocrinol (Lausanne); 2022; 13():968478. PubMed ID: 36225203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials.
    Lee MC; Hua YM; Yang CT; Kuo FH; Chang WT; Tang HJ; Siong Toh H; Lin YM; Chen SY; Chang HY; Liao CT
    Medicine (Baltimore); 2022 Dec; 101(51):e32489. PubMed ID: 36595871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.